Familial hypercholesterolaemia

Current Opinion in Cardiology

Volumn 29, Issue 4, 2014, Pages 381-388

  Nair, Devaki R ^a   Sharifi, Mahtab ^a   Al Rasadi, Khalid ^b  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

Author keywords

Familial hypercholesterolaemia; Guidelines for familial hypercholesterolaemia; Premature coronary heart disease

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; SUBTILISIN; HYPOCHOLESTEROLEMIC AGENT;

ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; AWARENESS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY CALCIFICATION; DUTCH CRITERIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENE MUTATION; GENETIC SCREENING; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIVER TRANSPLANTATION; MEDICAL HISTORY; MEDPED CRITERIA; PHENOTYPE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SCORING SYSTEM; SIMON BROOME CRITERIA; CORONARY DISEASE; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; MUTATION; PRACTICE GUIDELINE;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MUTATION; PRACTICE GUIDELINES AS TOPIC;

EID: 84904816929     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000083     Document Type: Review

References (79)

1. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014;171:309-325. Underdiagnosis of familial hypercholesterolaemia is a worldwide problem. This article deals with guidance to address a unified approach in treating familial hypercholesterolaemia. This attempt addresses the global issue in diagnosis and management.
2. Slack J. Inheritance of familial hypercholesterolemia. Atheroscler Rev 1979;5:35-66.
3. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303:893-896.
4. Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004;160:407-420.
5. Neil HA, Hammond T, Huxley R, et al. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000;321:148.
6. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012;223:262-268.
7. Kolansky DM, Cuchel M, Clark BJ, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008;102:1438-1443.
8. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013;381:1293-1301.
9. Stein EA, Raal FJ. Polygenic familial hypercholesterolaemia: does it matter? Lancet 2013;381:1255-1257.
10. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142:105-112.
11. Elis A, Zhou R, Stein EA. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Am J Cardiol 2011;108:223-226.
12. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34:3478-3490. The European guideline discusses the diagnosis of familial hypercholesterolaemia and aggressive management of familial hypercholesterolaemia to prevent premature coronary artery disease in this population. This article is recommended for nonspecialists to assist them in making a diagnosis of familial hypercholesterolaemia.
13. Besseling J, Kindt I, Hof M, et al. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14 000 mutation carriers. Atherosclerosis 2014;233:219-223.
14. Wierzbicki AS, Hardman TC, Viljoen A. New lipid-lowering drugs: an update. Int J Clin Pract 2012;66:270-280.
15. Ezzahti M, Sijbrands EJ, Mulder MT, et al. Familial hypercholesterolaemia: new treatment options. Neth J Med 2013;71:227-233.
16. Rees A. Familial hypercholesterolaemia: underdiagnosed and undertreated. Eur Heart J 2008;29:2583-2584.
17. Walzer S, Travers K, Rieder S, et al. Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey. Clinicoecon Outcomes Res 2013;5:189-192.
18. Steyn K, Goldberg YP, Kotze MJ, et al. Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations. Hum Genet 1996;98:479-484.
19. Izar MC, Machado VA, Fonseca FA. Genetic screening for homozygous and heterozygous familial hypercholesterolemia. Appl Clin Genet 2010;3:147-157.
20. Minhas R, Humphries SE, Davies D, et al. UK NICE Guideline on Identification and Management of FH (CG71). Internet. http://www.nice.org.uk/ CG071. 2013. [Accessed December 2013]
21. US MedPed Program. www.medped.org. [Accessed December 2013]
22. Wood D, Wray R, Poulter N, et al. JBS:2 Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):1-52.
23. Putting prevention first. NHS Health Check: vascular risk assessment and management best practice guidance. Department of Health 2009. http://www.dh.gov. uk/en/Publicationsandstatistics/Publications/Publications PolicyAndGuidance/DH- 097489. [Accessed 13 December 2012]
24. Calandra S, Tarugi P, Speedy HE, et al. Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk. J Lipid Res 2011;52:1885-1926.
25. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007;4:214-225.
26. Alves AC, Medeiros AM, Francisco V, et al. Molecular diagnosis of familial hypercholesterolemia: an important tool for cardiovascular risk stratification. Rev Port Cardiol 2010;29:907-921.
27. Kusters DM, de Beaufort C, Widhalm K, et al. Paediatric screening for hypercholesterolaemia in Europe. Arch Dis Child 2012;97:272-276.
28. Ito MK, McGowan MP, Moriarty PM. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5:S38-S45.
29. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
30. Innerarity TL, Mahley RW, Weisgraber KH, et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990;31:1337-1349.
31. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-156.
32. Arca M, Zuliani G, Wilund K, et al. Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 2002;359:841-847.
33. Pisciotta L, Priore Oliva C, Pes GM, et al. Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison. Atherosclerosis 2006;188:398-405.
34. Usifo E, Leigh SE, Whittall RA, et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet 2012;76:387-401.
35. Humphries SE, Cranston T, Allen M, et al. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med (Berl) 2006;84:203-214.
36. Glynou K, Laios E, Drogari E, et al. Development of a universal chemiluminometric genotyping method for high-throughput detection of 7 LDLR gene mutations in Greek population. Clin Biochem 2008;41:335-342.
37. Dedoussis GV, Schmidt H, Genschel J. LDL-receptor mutations in Europe. Hum Mutat 2004;24:443-459.
38. Leigh SE, Foster AH, Whittall RA, et al. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet 2008;72:485-498.
39. Taylor A, Wang D, Patel K, et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet 2010;77:572-580.
40. Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013;45:1274-1283.
41. Newson AJ, Humphries SE. Cascade testing in familial hypercholesterolaemia: how should family members be contacted? Eur J Hum Genet 2005;13:401-408.
42. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969;2:1380-1382.
43. Stone NJ, Levy RI, Fredrickson DS, et al. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974;49:476-488.
44. Jensen J, Blankenhorn DH, Kornerup V. Coronary disease in familial hypercholesterolemia. Circulation 1967;36:77-82.
45. Mabuchi H, Miyamoto S, Ueda K, et al. Causes of death in patients with familial hypercholesterolemia. Atherosclerosis 1986;61:1-6.
46. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008;29:2625-2633.
47. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004;256:482-490.
48. Mbewu AD, Bhatnagar D, Durrington PN, et al. Serum lipoprotein (a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb 1991;11:940-946.
49. Kusters DM, Wiegman A, Kastelein JJ, et al. Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res 2014;114:307-310.
50. Wendelhag I, Wiklund O, Wikstrand J. Arterial wall thickness in familial hypercholesterolemia. Ultrasound measurement of intima-media thickness in the common carotid artery. Arterioscler Thromb 1992;12:70-77.
51. ten Kate GL, ten Kate GJ, van den Oord SC, et al. Carotid plaque burden as a measure of subclinical coronary artery disease in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2013;111:1305-1310.
52. Clarke RE, Padayachee ST, Preston R, et al. Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. Heart 2013;99:175-180.
53. Gidding SS, Bookstein LC, Chomka EV. Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia. Circulation 1998;98:2580-2583.
54. Neefjes LA, Ten Kate GJ, Alexia R, et al. Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis 2011;219:721-727.
55. Plana N, Ferre R, Merino J, et al. Heterozygous familial hypercholesterolaemic patients have increased arterial stiffness, as determined using the augmentation index. J Atheroscler Thromb 2011;18:1110-1116.
56. Gylling H, Plat J, Turley S, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014;232:346-360.
57. Vuorio A, Docherty KF, Humphries SE, et al. Statin treatment of children with familial hypercholesterolemia - trying to balance incomplete evidence of longterm safety and clinical accountability: are we approaching a consensus? Atherosclerosis 2013;226:315-320. This is an important article as the controversy of treating children still continues without proper guidance. With increasing awareness of the condition, and success of cascade screening, more and more children will be diagnosed with familial hypercholesterolaemia. These children may need to be treated with a statin.
58. Girardi G. Can statins prevent pregnancy complications? J Reprod Immunol 2014;101-102:161-167.
59. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443.
60. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-581.
61. Moriarty PM. LDL-apheresis therapy. Curr Treat Options Cardiovasc Med 2006;8:282-288.
62. Gordon BR, Kelsey SF, Dau PC, et al. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. Am J Cardiol 1998;81:407-411.
63. Tatami R, Inoue N, Itoh H, et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators. Atherosclerosis 1992;95:1-13.
64. Waidner T, Franzen D, Voelker W, et al. The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study. Clin Investig 1994;72:858-863.
65. Schuff-Werner P, Gohlke H, Bartmann U, et al. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDLapheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation. Eur J Clin Invest 1994;24:724-732.
66. Thompsen J, Thompson PD. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006;189:31-38.
67. Stein EA. Other therapies for reducing low-density lipoprotein cholesterol: medications in development. Endocrinol Metab Clin North Am 2009;38:99-119.
68. Gotto AM Jr, Moon JE. Pharmacotherapies for lipid modification: beyond the statins. Nat Rev Cardiol 2013;10:560-570. Both lomitapide and mipomersen were approved for use in individuals with very high LDL-C, heterozygous or homozygous familial hypercholesterolaemia. The article would equip nonspecialists with the knowledge on development of new drugs for hyperlipidaemia.
69. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012;126:2283-2292.
70. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356:148-156.
71. Tardif JC, McGowan M, Ceska R, et al. Apolipoprotein B synthesis inhibition by mipomersen reduces low-density lipoprotein cholesterol when added to maximally tolerated lipid-lowering medication in patients with severe heterozygous hypercholesterolemia. J Am Coll Cardiol 2011;57:E492.
72. Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol 2007;18:304-309.
73. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-1118.
74. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36.
75. Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013;128:2113-2120.
76. Rhainds D, Arsenault BJ, Tardif JC. PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials. Clin Lipidol 2012;7:621-640.
77. Li C, Zhang W, Zhou F, et al. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis. PLoS One 2013;8:e77049.
78. Moini M, Mistry P, Schilsky ML. Liver transplantation for inherited metabolic disorders of the liver. Curr Opin Organ Transplant 2010;15:269-276.
79. Kassim SH, Li H, Bell P, et al. Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia. Hum Gene Ther 2013;24:19-26.